There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palatin Technologies (PTN – Research Report), Prestige Consumer Healthcare (PBH – Research Report) and CervoMed (CRVO – Research Report) with bullish sentiments.
Palatin Technologies (PTN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Palatin Technologies yesterday and set a price target of $6.00. The company’s shares closed last Wednesday at $2.07, close to its 52-week low of $1.43.
According to TipRanks.com, Newman is a 4-star analyst with an average return of
Palatin Technologies has an analyst consensus of Strong Buy, with a price target consensus of $9.33, representing a 322.2% upside. In a report issued on May 2, H.C. Wainwright also maintained a Buy rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Prestige Consumer Healthcare (PBH)
In a report released yesterday, Susan Anderson from Canaccord Genuity maintained a Buy rating on Prestige Consumer Healthcare, with a price target of $80.00. The company’s shares closed last Wednesday at $66.46.
According to TipRanks.com, Anderson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prestige Consumer Healthcare with a $77.50 average price target, which is a 21.4% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $75.00 price target.
CervoMed (CRVO)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed, with a price target of $65.00. The company’s shares closed last Wednesday at $24.72, close to its 52-week high of $26.38.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
CervoMed has an analyst consensus of Moderate Buy, with a price target consensus of $65.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTN:
- Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Is PTN a Buy, Before Earnings?
- Palatin’s IND application for obesity candidate granted FDA clearance
- Biotech Alert: Searches spiking for these stocks today
- Palatin presents results from Phase 3 PL9643 MELODY-1 trial
